Additional file 1: of Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

Patient perception of glatiramer acetate treatment efficacy by geographic region. aP < .0001 for Latin America vs. other geographic areas. (PDF 7 kb

Time course of spectrally determined (black line) and of drug-induced (grey line) BRS during the course of the modified Oxford maneuver.

<p>T0, baseline; T1, phenylephrine; T2 nitroprusside; T3, recovery. Data are means ± SD.</p

Correlation analysis of BRS estimates from the modified Oxford method and from trigonometric regressive spectral analysis (TRS).

<p>r, product-moment correlation coefficient; TRS-BRS, BRS determined by TRS under resting conditions; TRS-Phe, TRS-Nitro, BRS determined by TRS during application of phenylephrine (Phe) or nitroprusside (Nitro); Oxford-Phe, Oxford-Nitro, BRS determined by the modified Oxford maneuver using phenylephrine (Phe) or nitroprusside (Nitro).</p

Bland-Altman Plots for comparison of BRS estimates obtained from the modified Oxford method and trigonometric regressive spectral analysis (TRS).

<p>TRS-BRS, BRS determined by TRS during resting conditions; TRS-Phe, TRS-Nitro, BRS determined by TRS during application of phenylephrine (Phe) or nitroprusside (Nitro); Oxford-Phe, Oxford-Nitro, BRS determined by the modified Oxford maneuver using phenylephrine (Phe) or nitroprusside (Nitro).</p

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL - Fig 3

<p><b>Time to (a) 3-month and (b) 6-month confirmed disability progression, and (c) 3-month and (d) 6-month confirmed disability improvement in propensity-score-matched patients from the PANGAEA (fingolimod) and PEARL (BRACE) cohorts.</b> Kaplan–Meier estimate (cumulative distribution function) showing time to cumulative disability progression and time to cumulative disability improvement in propensity-score-matched patients from the PANGAEA (fingolimod) and PEARL (BRACE) cohorts. Not all matched patients had available Expanded Disability Status Scale scores and therefore some individuals could not be included in these analyses. BRACE, <u>B</u>etaseron^®, <u>R</u>ebif^®, <u>A</u>vonex^®, <u>C</u>opaxone^®, <u>E</u>xtavia^® (beta interferons or glatiramer acetate); PANGAEA, <u>P</u>ost-<u>a</u>uthorization <u>N</u>on-interventional <u>G</u>erman S<u>a</u>fety Study of Gil<u>e</u>ny<u>a</u>^® in Multiple Sclerosis Patients; PEARL, <u>P</u>rosp<u>e</u>ctive Ph<u>a</u>rmacoeconomic Coho<u>r</u>t Eva<u>l</u>uation.</p

Illustration of BRS estimation process.

<p>Spontaneous oscillations (top left) are replaced by theoretical TRS oscillations (top right). Calculation of BRS as slope of the regression line (bottom left) originating from coherent oscillation pairs (bottom right).</p

Systolic blood pressure (BP) and R-R interval (RRI) during the modified Oxford maneuver.

<p>Data are means ± SD.</p

Exemplified time course of systolic blood pressure (black line) and R-R interval (grey line) during the modified Oxford maneuver.

<p>Exemplified time course of systolic blood pressure (black line) and R-R interval (grey line) during the modified Oxford maneuver.</p